Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.
Inclusion Criteria:
Exclusion Criteria:
Gangwon-do, 24253, South Korea
Gangwon-do, 26426, South Korea
Gangwon-do, South Korea
Gyeongsangnam-do, 50612, South Korea
Jeollabuk-do, 54907, South Korea
Jeollanam-do, 58128, South Korea
Jeonlabuk-do, 54538, South Korea
Seoul, 01812, South Korea